Immuron Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Immuron wird ein jährliches Gewinn- und Umsatzwachstum von 22.4% bzw. 59.7% prognostiziert.

Wichtige Informationen

22.4%

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	15.3%
Wachstumsrate der Einnahmen	59.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	26 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

ASX:IMC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2026	15	-4	N/A	N/A	1
6/30/2025	6	-8	N/A	N/A	1
6/30/2024	5	-7	-6	-6	N/A
3/31/2024	4	-5	-5	-5	N/A
12/31/2023	4	-4	-4	-4	N/A
9/30/2023	3	-4	-3	-3	N/A
6/30/2023	2	-4	-3	-3	N/A
3/31/2023	1	-3	-2	-2	N/A
12/31/2022	1	-3	-2	-2	N/A
9/30/2022	1	-3	-2	-2	N/A
6/30/2022	1	-3	-3	-3	N/A
3/31/2022	1	-4	-3	-3	N/A
12/31/2021	0	-4	-4	-4	N/A
9/30/2021	0	-6	-4	-4	N/A
6/30/2021	0	-8	-4	-4	N/A
3/31/2021	1	-8	N/A	N/A	N/A
12/31/2020	1	-7	-4	-4	N/A
9/30/2020	2	-5	-4	-4	N/A
6/30/2020	3	-3	-3	-3	N/A
3/31/2020	3	-4	N/A	N/A	N/A
12/31/2019	3	-5	-3	-3	N/A
9/30/2019	3	-5	-2	-2	N/A
6/30/2019	2	-5	-2	-2	N/A
3/31/2019	2	-4	-1	-1	N/A
12/31/2018	2	-3	-1	-1	N/A
9/30/2018	2	-3	-2	-2	N/A
6/30/2018	2	-3	-4	-4	N/A
3/31/2018	2	-4	N/A	-6	N/A
12/31/2017	2	-5	N/A	-8	N/A
9/30/2017	2	-6	N/A	-8	N/A
6/30/2017	1	-7	N/A	-7	N/A
3/31/2017	1	-8	N/A	-5	N/A
12/31/2016	1	-6	N/A	-4	N/A
9/30/2016	1	-6	N/A	-5	N/A
6/30/2016	1	-7	N/A	-5	N/A
3/31/2016	1	-5	N/A	-5	N/A
12/31/2015	1	-4	N/A	-5	N/A
9/30/2015	1	-4	N/A	-4	N/A
6/30/2015	1	-3	N/A	-3	N/A
3/31/2015	1	-3	N/A	-3	N/A
12/31/2014	1	-2	N/A	-3	N/A
9/30/2014	1	-2	N/A	-3	N/A
6/30/2014	1	-2	N/A	-3	N/A
3/31/2014	1	-3	N/A	-2	N/A
12/31/2013	0	-3	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IMC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IMC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IMC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IMCDie Einnahmen des Unternehmens (59.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (5.7% pro Jahr).

Hohe Wachstumseinnahmen: IMCDie Einnahmen des Unternehmens (59.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IMC in 3 Jahren voraussichtlich hoch sein wird

Immuron Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Insufficient new directors

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Insufficient new directors

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

Have Insiders Been Selling Immuron Limited (ASX:IMC) Shares This Year?

New 90-day low: AU$0.21

New 90-day low: AU$0.21

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

New 90-day low: AU$0.23

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Full year earnings released - AU$0.017 loss per share

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

New 90-day high - AU$0.85

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken